MX2012005355A - Heart aging biomarkers and methods of use. - Google Patents

Heart aging biomarkers and methods of use.

Info

Publication number
MX2012005355A
MX2012005355A MX2012005355A MX2012005355A MX2012005355A MX 2012005355 A MX2012005355 A MX 2012005355A MX 2012005355 A MX2012005355 A MX 2012005355A MX 2012005355 A MX2012005355 A MX 2012005355A MX 2012005355 A MX2012005355 A MX 2012005355A
Authority
MX
Mexico
Prior art keywords
heart
methods
aging
biomarkers
heart aging
Prior art date
Application number
MX2012005355A
Other languages
Spanish (es)
Other versions
MX345333B (en
Inventor
Quinghong Li
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of MX2012005355A publication Critical patent/MX2012005355A/en
Publication of MX345333B publication Critical patent/MX345333B/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Abstract

The invention provides a set of robust biomarkers of aging in the heart comprising several genes involved in the Wnt signaling pathway. These genes have been found to be down-regulated in aged versus young heart tissue. Methods of using those biomarkers to monitor heart aging and to identify nutrients and dietary regimens for retarding heart aging are disclosed. Methods for the modulation of the genes themselves to retard heart aging are also disclosed.
MX2012005355A 2009-11-10 2010-11-09 Heart aging biomarkers and methods of use. MX345333B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28087909P 2009-11-10 2009-11-10
PCT/US2010/002950 WO2011059490A1 (en) 2009-11-10 2010-11-09 Heart aging biomarkers and methods of use

Publications (2)

Publication Number Publication Date
MX2012005355A true MX2012005355A (en) 2012-05-29
MX345333B MX345333B (en) 2017-01-25

Family

ID=43991901

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012005355A MX345333B (en) 2009-11-10 2010-11-09 Heart aging biomarkers and methods of use.

Country Status (12)

Country Link
US (1) US20120220488A1 (en)
EP (1) EP2499260B1 (en)
JP (1) JP5901530B2 (en)
CN (1) CN102695807B (en)
AU (1) AU2010318703B2 (en)
BR (1) BR112012011133A2 (en)
CA (1) CA2779606A1 (en)
ES (1) ES2641491T3 (en)
IN (1) IN2012DN03954A (en)
MX (1) MX345333B (en)
RU (1) RU2562174C2 (en)
WO (1) WO2011059490A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5808825B2 (en) * 2011-02-24 2015-11-10 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド Compositions and methods for diagnosing and treating cat renal disorders
CN105868532B (en) * 2016-03-22 2019-03-05 曾金生 A kind of method and system of intelligent evaluation heart aging degree
WO2018081175A1 (en) 2016-10-24 2018-05-03 Habit, Llc System and method for implementing meal selection based on vitals, genotype, and phenotype
CN110157788A (en) * 2019-04-04 2019-08-23 东莞市第八人民医院（东莞市儿童医院） A kind of primer, probe and kit for quantitative detection SENP2 mRNA level in-site
CN111366736A (en) * 2020-03-31 2020-07-03 中国科学院昆明动物研究所 Serum protein marker for indicating healthy aging key pathway and application thereof
US11139064B1 (en) * 2020-12-29 2021-10-05 Kpn Innovations, Llc. Systems and methods for generating a body degradation reduction program
US20220208347A1 (en) * 2020-12-29 2022-06-30 Kpn Innovations, Llc. Systems and methods for generating a body degradation reduction program

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2112543C1 (en) * 1996-09-26 1998-06-10 Александр Григорьевич Хоменко Immunomodulating drug
CA2381777C (en) * 1999-08-12 2011-10-04 Wisconsin Alumni Research Foundation Identification of genetic markers of biological age and metabolism
DE60039190D1 (en) 1999-12-23 2008-07-24 Univ California MEASURES THAT EFFECT THE EFFECTS OF A CALORIC RESTRICTION
US6406853B1 (en) 1999-12-23 2002-06-18 The Regents Of The University Of California Interventions to mimic the effects of calorie restriction
DK1549353T3 (en) * 2002-10-09 2010-07-12 Central Iowa Health System Use of alpha (1,3) galactosyltransferase expressing allogeneic tumor cells for vaccination against tumors
US20050013776A1 (en) 2003-07-16 2005-01-20 Spindler Stephen R. Methods of evaluating the dynamics of caloric restriction and identifying caloric restriction mimetics
US20040191775A1 (en) 2003-03-12 2004-09-30 Spindler Stephen R. Methods of analyzing genes affected by caloric restriction or caloric restriction mimetics
US20040180003A1 (en) 2003-03-12 2004-09-16 Spindler Stephen R. Methods of screening for caloric restriction mimetics and reproducing effects of caloric restriction
WO2005002672A2 (en) * 2003-07-01 2005-01-13 President And Fellows Of Harvard College Sirt1 modulators for manipulating cells/organism lifespan/stress response
JP5331476B2 (en) * 2005-06-15 2013-10-30 カリダ・ジェノミックス・インコーポレイテッド Single molecule array for genetic and chemical analysis
US20070196850A1 (en) * 2006-01-27 2007-08-23 University Of Washington Identification of aging genes through large-scale analysis
RU2449554C2 (en) 2006-02-01 2012-05-10 Нестек С.А. Food systems and longevity enhancement methods
EP2084263A4 (en) * 2006-11-09 2011-06-22 David Gladstone Inst Methods for inducing cardiomyogenesis
WO2008098184A2 (en) * 2007-02-09 2008-08-14 The General Hospital Corporation Methods for the induction of a cell to enter the islet 1+ lineage and a method for the expansion thereof
CA2713388C (en) * 2008-01-14 2016-03-29 William Scott Sulfone substituted 2,3-dihydroimidazo [1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis

Also Published As

Publication number Publication date
WO2011059490A1 (en) 2011-05-19
EP2499260A4 (en) 2013-07-17
JP5901530B2 (en) 2016-04-13
RU2562174C2 (en) 2015-09-10
CA2779606A1 (en) 2011-05-19
IN2012DN03954A (en) 2015-08-07
CN102695807B (en) 2016-02-24
MX345333B (en) 2017-01-25
AU2010318703B2 (en) 2016-08-25
CN102695807A (en) 2012-09-26
BR112012011133A2 (en) 2016-07-05
JP2013509877A (en) 2013-03-21
RU2012123990A (en) 2013-12-20
ES2641491T3 (en) 2017-11-10
AU2010318703A1 (en) 2012-05-31
EP2499260B1 (en) 2017-08-23
US20120220488A1 (en) 2012-08-30
EP2499260A1 (en) 2012-09-19

Similar Documents

Publication Publication Date Title
MX345333B (en) Heart aging biomarkers and methods of use.
IL242842A (en) Methods for the detection and diagnosis of heart rhythm disorders
HRP20171352T1 (en) Wnt antagonists and methods of treatment
EP2614369A4 (en) Inhibitors of human ezh2, and methods of use thereof
HK1205938A1 (en) Inhibitors of human ezh2, and methods of use thereof ezh2
DK2608777T3 (en) Compositions and Methods for Cardiac Therapy
EP2611822A4 (en) Compositions for labeling nerves and methods of use
ZA201300319B (en) Compositions and methods for modulating the wnt signaling pathway
EP2569633A4 (en) Compositions and methods of identifying tumor specific neoantigens
HK1178074A1 (en) Compositions and methods for the diagnosis and treatment of tumor
IL220290A0 (en) Stem cell immune modulation methods of use and apparatus
EP2632414A4 (en) Methods and compositions suitable for promoting healthy skin
HK1202243A1 (en) Methods for improving cognitive function and decreasing heart rate
EP2809153B8 (en) Apparatus for testing, assessment, and maintenance of harvested hearts for transplanting
AU2010306870A8 (en) Reducing the risk of pathological effects of traumatic brain injury
EP2606123A4 (en) Methods of generating oligodendrocytes and cell populations comprising same
IL225793A0 (en) Methods and compositions for the treatment of insulin-associated medical conditions
IL240560A0 (en) Compositions and methods for the diagnosis and treatment of tumor
EP2164978A4 (en) Compositions and methods for modulation of adamts13 activity
WO2011150393A9 (en) Methods for improving maternal and fetal health
HK1206631A1 (en) Methods and compositions for treatment of traumatic brain injury and for modulation of migration of neurogenic cells
EP2603609A4 (en) Treatment and diagnosis of epigenetic disorders and conditions
EP2403518A4 (en) Compositions and methods for modulation of cell migration
HK1258467A1 (en) Methods and compositions for prevention and treatment of cardiac hypertrophy
WO2011109768A9 (en) Compositions and methods for modulating cardiac conditions

Legal Events

Date Code Title Description
FG Grant or registration